Pfizer and Teva concluded their presentation of evidence on the 11th day of the bench trial in front of Judge Smith, in the Norfolk Division of the EDVA.  Closing arguments were set for July 13.  As we previously noted in our coverage of the case here, much of this trial was about Pfizer's standing to enforce the patent-in-suit, and Teva's allegations of inequitable conduct by Pfizer during prosecution of the patent-in-suit, as Teva has already stipulated to indirect infringement.